There are no significant Insider Shareholders in Cullinan Therapeutics as of December 12, 2025.
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Capital Management Lp Lynx1 | 8,963,500 | 30 Oct, 2025 | |
| Ansbert Gadicke | 7,892,819 | 20 Sep, 2021 | |
| Oncology Impact Fund L.P. Ubs | 7,648,268 | 20 Sep, 2021 | |
| Vision Scs F2 | 1,255,963 | 04 Aug, 2022 | |
| Morana Jovan-Embiricos | 829,978 | 28 Jun, 2022 | |
| Bioscience I 2017 Ltd F2 | 537,392 | 23 Jun, 2022 | |
| Owen Hughes | President And CEO | 506,226 | 14 Jan, 2021 |
| Nadim Ahmed | President And CEO | 430,621 | 27 Feb, 2025 |
| Corrine Savill | Chief Business Officer | 240,990 | 21 Feb, 2025 |
| Thomas Ebeling | 186,653 | 11 Jun, 2024 | |
| Jeffrey Alan Jones | Chief Medical Officer | 174,164 | 27 Feb, 2025 |
| Jennifer Michaelson | Chief Scientific Officer | 138,004 | 25 Nov, 2025 |
| Jacquelyn L Sumer | Chief Legal Officer | 136,895 | 27 Feb, 2025 |
| Jeffrey Trigilio | Chief Financial Officer | 133,919 | 23 Feb, 2024 |
| Patrick Baeuerle | Chief Scientific Officer | 76,000 | 21 Feb, 2023 |
| Leigh Zawel | 69,785 | 15 Feb, 2022 | |
| Partners L P/Il Bvf | 64,161 | 19 Jan, 2023 | |
| Mary Kay Fenton | Chief Financial Officer | 60,000 | 21 Feb, 2025 |
| Raymond T Keane | Chief Legal Officer | 24,124 | 15 Feb, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 24 Nov, 2025 | Jennifer Michaelson | Common Stock | D | 4,000 | $12.30 | 138,004 | D | S |
| 28 Oct, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share | A | 165,667 | $8.40 | 8,963,500 | I | P |
| 14 Oct, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share ("Common Stock") | A | 15,032 | $7.59 | 8,564,116 | I | P |
| 15 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 51,500 | $7.94 | 8,615,616 | I | P |
| 16 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 150,000 | $8.86 | 8,765,616 | I | P |
| 17 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 32,217 | $7.84 | 8,797,833 | I | P |
| 08 Oct, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share ("Common Stock") | A | 556,300 | $6.46 | 7,645,743 | I | P |
| 09 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 626,043 | $6.70 | 8,271,786 | I | P |
| 10 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 277,298 | $7.36 | 8,549,084 | I | P |
| 25 Feb, 2025 | Jeffrey Alan Jones | Common Stock | D | 4,895 | $8.53 | 174,164 | D | S |
| 25 Feb, 2025 | Jennifer Michaelson | Common Stock | D | 3,756 | $8.53 | 142,004 | D | S |
| 25 Feb, 2025 | Nadim Ahmed | Common Stock | D | 12,529 | $8.53 | 430,621 | D | S |
| 25 Feb, 2025 | Jacquelyn L Sumer | Common Stock | D | 3,756 | $8.53 | 136,895 | D | S |
| 25 Feb, 2025 | Nadim Ahmed | - | - | 430,621 | D | |||
| 19 Feb, 2025 | Jeffrey Alan Jones | Common Stock | A | 65,000 | $0.00 | 179,059 | D | A |
| 19 Feb, 2025 | Jacquelyn L Sumer | - | - | 140,651 | D | |||
| 19 Feb, 2025 | Nadim Ahmed | Common Stock | A | 180,000 | $0.00 | 443,150 | D | A |
| 19 Feb, 2025 | Corrine Savill | Common Stock | A | 37,500 | $0.00 | 240,990 | D | A |
| 19 Feb, 2025 | Jacquelyn L Sumer | Common Stock | A | 50,000 | $0.00 | 140,651 | D | A |
| 19 Feb, 2025 | Mary Kay Fenton | Common Stock | A | 60,000 | $0.00 | 60,000 | D | A |